Search Results - "Neuzillet C"

This result is not displayed to guests.
Login for full access.

PO-1263 Exclusive radiotherapy in early stage anal cancer - outcomes, patterns and predictors of relapse.

Authors: Briens, A. Neuzillet, C. Huguet, F. et al.

Source: Radiotherapy & Oncology. 2021 Supplement 1, Vol. 161, pS1042-S1043. 2p.

Subjects: Anal cancer, Tumor classification, Radiotherapy

60P Epidemiology and patterns of care of intrahepatic cholangiocarcinoma (iCCA) in France: Real life data from the French National Hospital-Discharge Summaries database system (PMSI).

Authors: Neuzillet, C. Emery, C. Teissier, C. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS264-S264. 1p.

Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.

Authors: Schram, A. M. Goto, K. Kim, D.-W. et al.

Source: New England Journal of Medicine. 2/6/2025, Vol. 392 Issue 6, p566-576. 11p.

Physical activity in patients with unresectable pancreatic adenocarcinoma: A multicentric randomized controlled study (APACaP study).

Authors: Neuzillet, C. Vergnault, M. Touillaud, M. et al.

Source: Annals of Physical & Rehabilitation Medicine. Oct2013, Vol. 56, pe247-e248. 0p.

Étude multicentrique randomisée d’évaluation d’un programme d’activité physique adaptée chez des malades ayant un cancer du pancréas non résécable (APACaP).

Authors: Neuzillet, C. Vergnault, M. Touillaud, M. et al.

Source: Annals of Physical & Rehabilitation Medicine. Oct2013, Vol. 56, pe245-e245. 1p.

398 Benchmarking the Allosteric MEK Inhibitors UO126, AZD6244, AS703026, and GSK1120212 Shows Differences in Potency to Inhibit ERK Phosphorylation, Proliferation, and Invasion in Pancreatic Cancer Models

Authors: Neuzillet, C. Serova, M. Raballand, A. et al.

Source: European Journal of Cancer. Nov2012 Supplement, Vol. 48, p121-121. 1p.

402 Dual Inhibition of the MEK and the PI3K-Akt-mTOR Pathways Using GSK1120212 (or UO126) and Everolimus Overcomes Resistance to MEK Inhibitors Used as Single Agents in Pancreatic Cancer Cells

Authors: Neuzillet, C. Serova, M. Raballand, A. et al.

Source: European Journal of Cancer. Nov2012 Supplement, Vol. 48, p122-122. 1p.

Brèves de l'AERIO.

Alternate Title: AERIO News in Brief.

Authors: Thibault, C. Taïeb, J. Arrondeau, J. et al.

Source: Oncologie (Tech Science Press). Feb2014, Vol. 16 Issue 2/3, p148-151. 4p.

2886P Impact of 7,091 patients (pts) with cancer treated in 110 centers in France and Belgium of remote patient monitoring on nutritional status and quality of life (QoL) in cancer patients across a cohort.

Authors: Scotté, F. Raynard, B. Cardenas Braz, D. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1520-S1520. 1p.

80MO Durvalumab (D) plus tremelimumab (T) in advanced biliary tract carcinoma (BTC) patients (Pts) after failure of platinum-based chemotherapy (CTx): Final results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 phase II trial.

Authors: Delaye, M. Assenat, E. Dahan, L. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS233-S233. 1p.

595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC).

Authors: Kim, D-W. Goto, K. Schram, A. et al.

Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1702-S1703. 2p.

1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC).

Authors: Schram, A. Macarulla, T. Cleary, J. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS895-S896. 2p.

1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC).

Authors: Schram, A. Goto, K. Kim, D-W. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS756-S757. 2p.

557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial.

Authors: Coutzac, C. Bigot, F. Vansteene, D. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS415-S415. 1p.

1566TiP PRODIGE 65 - UCGI 36 - GEMPAX : A unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma.

Authors: de la Fouchardiere, C. Hammel, P. Launay, S. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS954-S955. 2p.

52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial.

Authors: Phelip, J.M. Desrame, J. Edeline, J. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS260-S261. 2p.

LBA60 Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study.

Authors: de la Fouchardiere, C. Malka, D. Chabaud, S. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1426-S1426. 1p.

1487TiP A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM – D17-01 PRODIGE 63 STUDY)

Authors: Hilmi, M. Hautefeuille, V. Lambert, A. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS1095-S1095. 1p.

75P Tumor mutational burden in clinical routine practice: Identifying the right threshold?

Authors: Dupain, C. Gutman, T. Girard, E. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS388-S388. 1p.